Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 13/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | IDO1 | P14902 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348853 | 0.82 | HDAC6 (0.70) | HDAC6HDAC8HDAC1CA1CA9 | |
| SCHEMBL2690287 | 0.82 | HDAC1 (0.69) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL28299068 | 0.80 | HDAC8 (1.00) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL28895973 | 0.80 | HDAC8 (1.00) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL21755109 | 0.80 | HDAC8 (1.00) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| Benzohydroxamate SCHEMBL133061 | 0.80 | HDAC8 (1.00) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL2407104 | 0.79 | ALDH1A1 (0.65) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL2407916 | 0.79 | ALDH1A1 (0.65) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL2405281 | 0.79 | ALDH1A1 (0.65) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL1552114 | 0.79 | HDAC1 (0.64) | HDAC6HDAC8HDAC1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318361-B1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8841291-B2 | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2014-01-30 | — | — | US | disclosed |
| CN-102143942-A | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG | 2011-08-03 | — | — | CN | disclosed |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| EP-2318361-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010007027-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | HDAC6 43/4885HDAC8 80/4885HDAC1 39/4885 |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | HDAC6 41/4885HDAC8 82/4885HDAC1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.